These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32695229)

  • 1. Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol.
    Gal R; Praksch D; Kenyeres P; Rabai M; Toth K; Halmosi R; Habon T
    Cardiovasc Ther; 2020; 2020():7262474. PubMed ID: 32695229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moderate red wine consumption improves hemorheological parameters in healthy volunteers.
    Toth A; Sandor B; Papp J; Rabai M; Botor D; Horvath Z; Kenyeres P; Juricskay I; Toth K; Czopf L
    Clin Hemorheol Microcirc; 2014; 56(1):13-23. PubMed ID: 23089888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone Replacement Therapy in Deficient Patients With Chronic Heart Failure: A Randomized Double-Blind Controlled Pilot Study.
    Navarro-Peñalver M; Perez-Martinez MT; Gómez-Bueno M; García-Pavía P; Lupón-Rosés J; Roig-Minguell E; Comin-Colet J; Bayes-Genis A; Noguera JA; Pascual-Figal DA
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):543-550. PubMed ID: 29929385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical assessment of complementary treatment with Qishen Yiqi dripping pills on ischemic heart failure: study protocol for a randomized, double-blind, multicenter, placebo-controlled trial (CACT-IHF).
    Hou YZ; Wang S; Zhao ZQ; Wang XL; Li B; Soh SB; Mao JY
    Trials; 2013 May; 14():138. PubMed ID: 23672353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of Qishen granules in patients with chronic heart failure: study protocol for a randomized controlled trial.
    Wang J; Shi J; Wei J; Wang J; Gao K; Li X; Chen J; Li S; Zhao H; Wang W
    Trials; 2017 Oct; 18(1):468. PubMed ID: 29017565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Inorganic Nitrate Versus Placebo Treatment in Heart Failure with Preserved Ejection Fraction.
    Gui Y; Chen J; Hu J; Ouyang M; Deng L; Liu L; Sun K; Tang Y; Xiang Q; Xu J; Zhu L; Peng Z; Zou P; Li B; Zheng Z; Xu D
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):503-513. PubMed ID: 32394177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials.
    Lei L; Liu Y
    BMC Cardiovasc Disord; 2017 Jul; 17(1):196. PubMed ID: 28738783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
    Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
    Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Nanayakkara S; Byrne M; Mak V; Carter K; Dean E; Kaye DM
    J Am Heart Assoc; 2020 Jul; 9(13):e015026. PubMed ID: 32552264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure.
    Pei H; Miao W; Xie WZ; Wang W; Zhao D; Su GH; Zhao Z
    Int Heart J; 2019 Jul; 60(4):899-909. PubMed ID: 31308326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction.
    Borlaug BA; Koepp KE; Melenovsky V
    J Am Coll Cardiol; 2015 Oct; 66(15):1672-82. PubMed ID: 26449137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of low dose aluminum on hemorheological and hematological parameters in rats.
    Turgut S; Bor-Kucukatay M; Emmungil G; Atsak P; Turgut G
    Arch Toxicol; 2007 Jan; 81(1):11-7. PubMed ID: 16721596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial.
    Kim KH; Kim HK; Hwang IC; Lee SP; Cho HJ; Kang HJ; Kim YJ; Sohn DW
    Trials; 2013 Jun; 14():188. PubMed ID: 23799908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Zheng SL; Chan FT; Nabeebaccus AA; Shah AM; McDonagh T; Okonko DO; Ayis S
    Heart; 2018 Mar; 104(5):407-415. PubMed ID: 28780577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
    Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
    JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose.
    Pierce JD; Mahoney DE; Hiebert JB; Thimmesch AR; Diaz FJ; Smith C; Shen Q; Mudaranthakam DP; Clancy RL
    BMC Cardiovasc Disord; 2018 Apr; 18(1):57. PubMed ID: 29606104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical assessment of Shenfu injection loading in the treatment of patients with exacerbation of chronic heart failure due to coronary heart disease: study protocol for a randomized controlled trial.
    Liu C; Hou Y; Wang X; Zhao Z; Liu Z; Zhai J; Mao J; Shang H
    Trials; 2015 May; 16():222. PubMed ID: 25994188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.
    Daubert MA; Yow E; Dunn G; Marchev S; Barnhart H; Douglas PS; O'Connor C; Goldstein S; Udelson JE; Sabbah HN
    Circ Heart Fail; 2017 Dec; 10(12):. PubMed ID: 29217757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2).
    Van Tassell BW; Buckley LF; Carbone S; Trankle CR; Canada JM; Dixon DL; Abouzaki N; Oddi-Erdle C; Biondi-Zoccai G; Arena R; Abbate A
    Clin Cardiol; 2017 Sep; 40(9):626-632. PubMed ID: 28475816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.